TROSPIUM CHLORIDE ONCE‐DAILY EXTENDED RELEASE IS EFFICACIOUS AND TOLERATED IN ELDERLY SUBJECTS (AGED ≥75 YEARS) WITH OVERACTIVE BLADDER SYNDROME

© 2 0 11 T H E A U T H O R S 6 2 0 B J U I N T E R N A T I O N A L © 2 0 11 B J U I N T E R N A T I O N A L 20 Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire; the OAB-q. Qual Life Res 2002; 11: 563–74 21 Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH. How much is enough and who says so? BJOG 2004; 111: 605– 12 22 Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome; an integrated analysis of two randomised, phase III trials. Int J Clin Pract 2009; 63: 1715–23 23 Abrams P, Malone-Lee J, Jacquetin B et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551–60 24 Haab F, Corcos J, Siami P et al. Longterm treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025–32 25 Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376–84 26 Appell R, Anderson R, Gittelman M. Efficacy, safety and tolerability of oncedaily oxybutynin in elderly patients. J Am Geriatr Soc 2000; 48: S81 27 Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome; a pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14–24 28 Allergan, Inc. Data on file 29 Rovner E, Dmochowski R, Watanabe J. Once daily trospium chloride 60 mg extended release is safe and effective in patients with the overactive bladder syndrome who use multiple concomitant medications. Neurourol Urodyn 2009; 28: 146–7 30 Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 2007; 100: 1007–14 31 Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010; 106: 268–74 32 Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317–26 33 Sandage B, Lerch G, Larsen G, Profy A. Trospium chloride does not cross the blood-brain barrier of male Long Evans rats. Neurology 2009; 72 (Suppl. 3): A50 34 Geyer J, Gavrilova O, Petzinger E. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009; 37: 1371–4 35 Bolge SC, Cerulli A, Kahler KH, Gause D. Impact of successful treatment of overactive bladder on health care resource use and productivity. Drug Benefit Trends 2006; 18: 244–55 36 Brown JS, Vittinghoff E, Wyman JF et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48: 721–5 37 Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005; 25: 511–19 38 Neubauer DN. Sleep problems in the elderly. Am Fam Physician 1999; 59: 2551–8 39 Stone KL, Ancoli-Israel S, Blackwell T et al. Actigraphy-measured sleep characteristics and risk of falls in older women. Arch Intern Med 2008; 168: 1768–75 40 Isik AT, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13: 672–6